{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T17:54:35Z","timestamp":1794851675880,"version":"4.9.1"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,9,4]],"date-time":"2023-09-04T00:00:00Z","timestamp":1693785600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,4]],"date-time":"2023-09-04T00:00:00Z","timestamp":1693785600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["17pc0101006"],"award-info":[{"award-number":["17pc0101006"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["17pc0101006"],"award-info":[{"award-number":["17pc0101006"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["17pc0101006"],"award-info":[{"award-number":["17pc0101006"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["17pc0101006"],"award-info":[{"award-number":["17pc0101006"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["17pc0101006"],"award-info":[{"award-number":["17pc0101006"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Plasma biomarkers have emerged as promising screening tools for Alzheimer\u2019s disease (AD) because of their potential to detect amyloid \u03b2 (A\u03b2) accumulation in the brain. One such candidate is the plasma A\u03b242\/40 ratio (A\u03b242\/40). Unlike previous research that used traditional immunoassay, recent studies that measured plasma A\u03b242\/40 using fully automated platforms reported promising results. However, its utility should be confirmed using a broader patient population, focusing on the potential for early detection.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We recruited 174 participants, including healthy controls (HC) and patients with clinical diagnoses of AD, frontotemporal lobar degeneration, dementia with Lewy bodies\/Parkinson\u2019s disease, mild cognitive impairment (MCI), and others, from a university memory clinic. We examined the performance of plasma A\u03b242\/40, measured using the fully automated high-sensitivity chemiluminescence enzyme (HISCL) immunoassay, in detecting amyloid-positron emission tomography (PET)-derived A\u03b2 pathology. We also compared its performance with that of Simoa-based plasma phosphorylated tau at residue 181 (p-tau181), glial fibrillary acidic protein (GFAP), and neurofilament light (NfL).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Using the best cut-off derived from the Youden Index, plasma A\u03b242\/40 yielded an area under the receiver operating characteristic curve (AUC) of 0.949 in distinguishing visually assessed\n                      <jats:sup>18<\/jats:sup>\n                      F-Florbetaben amyloid PET positivity. The plasma A\u03b242\/40 had a significantly superior AUC than p-tau181, GFAP, and NfL in the 167 participants with measurements for all four biomarkers. Next, we analyzed 99 participants, including only the HC and those with MCI, and discovered that plasma A\u03b242\/40 outperformed the other plasma biomarkers, suggesting its ability to detect early amyloid accumulation. Using the Centiloid scale (CL), Spearman\u2019s rank correlation coefficient between plasma A\u03b242\/40 and CL was -0.767. Among the 15 participants falling within the CL values indicative of potential future amyloid accumulation (CL between 13.5 and 35.7), plasma A\u03b242\/40 categorized 61.5% (8\/13) as A\u03b2-positive, whereas visual assessment of amyloid PET identified 20% (3\/15) as positive.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Plasma A\u03b242\/40 measured using the fully automated HISCL platform showed excellent performance in identifying A\u03b2 accumulation in the brain in a well-characterized cohort. This equipment may be useful for screening amyloid pathology because it has the potential to detect early amyloid pathology and is readily applied in clinical settings.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13195-023-01296-5","type":"journal-article","created":{"date-parts":[[2023,9,4]],"date-time":"2023-09-04T07:02:33Z","timestamp":1693810953000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Performance of plasma A\u03b242\/40, measured using a fully automated immunoassay, across a broad patient population in identifying amyloid status"],"prefix":"10.1186","volume":"15","author":[{"given":"Shogyoku","family":"Bun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiki","family":"Tezuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahito","family":"Kubota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Takahata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sho","family":"Moriguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin","family":"Kurose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Momota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natsumi","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayaka","family":"Morimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuka","family":"Hoshino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morinobu","family":"Seki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Mimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Shikimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuharu","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Hoshino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiaki","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hajime","family":"Tabuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaru","family":"Mimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,4]]},"reference":[{"key":"1296_CR1","unstructured":"World Health Organization: Global action plan on the public health response to de-mentia 2017\u20132025. https:\/\/www.who.int\/publications\/i\/item\/global-action-plan-on-the-public-health-response-to-dementia-2017---2025. Accessed 22 Dec 2022."},{"issue":"4","key":"1296_CR2","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1097\/NEN.0b013e31824b211b","volume":"71","author":"TG Beach","year":"2012","unstructured":"Beach TG, Monsell SE, Phillips LE, Kukull W. Accuracy of the Clinical Diagnosis of Alzheimer Disease at National Institute on Aging Alzheimer\u2019s Disease Centers, 2005\u20132010. J Neuropathol Exp Neurol. 2012;71(4):266\u201373. https:\/\/doi.org\/10.1097\/NEN.0b013e31824b211b.","journal-title":"J Neuropathol Exp Neurol"},{"issue":"1","key":"1296_CR3","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41583-019-0240-3","volume":"21","author":"R van der Kant","year":"2020","unstructured":"van der Kant R, Goldstein LSB, Ossenkoppele R. Amyloid-\u03b2-independent regulators of tau pathology in Alzheimer disease. Nat Rev Neurosci. 2020;21(1):21\u201335. https:\/\/doi.org\/10.1038\/s41583-019-0240-3.","journal-title":"Nat Rev Neurosci"},{"issue":"4","key":"1296_CR4","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack","year":"2018","unstructured":"Jack CR, Bennett DA, Blennow K, et al. NIA-AA Research Framework: toward a bio-logical definition of Alzheimer\u2019s disease. Alzheimers Dement. 2018;14(4):535\u201362. https:\/\/doi.org\/10.1016\/j.jalz.2018.02.018.","journal-title":"Alzheimers Dement"},{"issue":"7","key":"1296_CR5","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/S1474-4422(16)00070-3","volume":"15","author":"B Olsson","year":"2016","unstructured":"Olsson B, Lautner R, Andreasson U, et al. CSF and blood biomarkers for the diag-nosis of Alzheimer\u2019s disease: a systematic review and meta-analysis. Lancet Neurol. 2016;15(7):673\u201384. https:\/\/doi.org\/10.1016\/S1474-4422(16)00070-3.","journal-title":"Lancet Neurol"},{"key":"1296_CR6","doi-asserted-by":"publisher","unstructured":"Palmqvist S, Stomrud E, Cullen N, et al. An accurate fully automated panel of plas-ma biomarkers for Alzheimer\u2019s disease. Alzheimers Dement. https:\/\/doi.org\/10.1002\/alz.12751. Published online August 2022.","DOI":"10.1002\/alz.12751"},{"key":"1296_CR7","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.bbrc.2021.08.066","volume":"576","author":"K Yamashita","year":"2021","unstructured":"Yamashita K, Watanabe S, Ishiki K, et al. Fully automated chemiluminescence en-zyme immunoassays showing high correlation with immunoprecipitation mass spectrom-etry assays for \u03b2-amyloid (1\u201340) and (1\u201342) in plasma samples. Biochem Biophys Res Commun. 2021;576:22\u20136. https:\/\/doi.org\/10.1016\/j.bbrc.2021.08.066.","journal-title":"Biochem Biophys Res Commun"},{"key":"1296_CR8","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s13195-022-01029-0","volume":"14","author":"K Yamashita","year":"2022","unstructured":"Yamashita K, Miura M, Watanabe S, et al. Fully automated and highly specific plas-ma \u03b2-amyloid immunoassays predict \u03b2-amyloid status defined by amyloid positron emis-sion tomography with high accuracy. Alzheimers Res Ther. 2022;14:86. https:\/\/doi.org\/10.1186\/s13195-022-01029-0.","journal-title":"Alzheimers Res Ther"},{"issue":"3","key":"1296_CR9","doi-asserted-by":"publisher","first-page":"e264","DOI":"10.1212\/WNL.0000000000201389","volume":"100","author":"S Shimohama","year":"2023","unstructured":"Shimohama S, Tezuka T, Takahata K, et al. Impact of amyloid and tau PET on changes in diagnosis and patient management. Neurology. 2023;100(3):e264\u201374. https:\/\/doi.org\/10.1212\/WNL.0000000000201389.","journal-title":"Neurology"},{"key":"1296_CR10","doi-asserted-by":"publisher","unstructured":"Chatterjee P, Pedrini S, Doecke JD, et al. Plasma A\u03b242\/40 ratio, p-tau181, GFAP, and NfL across the Alzheimer\u2019s disease continuum: a cross-sectional and longitudinal study in the AIBL cohort. Alzheimers Dement.\u00a0https:\/\/doi.org\/10.1002\/alz.12724. Published online July 2022.","DOI":"10.1002\/alz.12724"},{"issue":"3","key":"1296_CR11","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","volume":"7","author":"GM McKhann","year":"2011","unstructured":"McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 2011;7(3):263\u20139. https:\/\/doi.org\/10.1016\/j.jalz.2011.03.005.","journal-title":"Alzheimers Dement"},{"issue":"6","key":"1296_CR12","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1002\/mds.26987","volume":"32","author":"GU H\u00f6glinger","year":"2017","unstructured":"H\u00f6glinger GU, Respondek G, Stamelou M, et al. Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria. Mov Disord. 2017;32(6):853\u201364. https:\/\/doi.org\/10.1002\/mds.26987.","journal-title":"Mov Disord"},{"issue":"5","key":"1296_CR13","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1212\/WNL.0b013e31827f0fd1","volume":"80","author":"MJ Armstrong","year":"2013","unstructured":"Armstrong MJ, Litvan I, Lang AE, et al. Criteria for the diagnosis of corticobasal de-generation. Neurology. 2013;80(5):496\u2013503. https:\/\/doi.org\/10.1212\/WNL.0b013e31827f0fd1.","journal-title":"Neurology"},{"issue":"9","key":"1296_CR14","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1093\/brain\/awr179","volume":"134","author":"K Rascovsky","year":"2011","unstructured":"Rascovsky K, Hodges JR, Knopman D, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain. 2011;134(9):2456\u201377. https:\/\/doi.org\/10.1093\/brain\/awr179.","journal-title":"Brain"},{"issue":"11","key":"1296_CR15","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1212\/WNL.0b013e31821103e6","volume":"76","author":"ML Gorno-Tempini","year":"2011","unstructured":"Gorno-Tempini ML, Hillis AE, Weintraub S, et al. Classification of primary progressive aphasia and its variants. Neurology. 2011;76(11):1006\u201314. https:\/\/doi.org\/10.1212\/WNL.0b013e31821103e6.","journal-title":"Neurology"},{"issue":"3","key":"1296_CR16","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.jalz.2011.03.008","volume":"7","author":"MS Albert","year":"2011","unstructured":"Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impair-ment due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 2011;7(3):270\u20139. https:\/\/doi.org\/10.1016\/j.jalz.2011.03.008.","journal-title":"Alzheimers Dement"},{"key":"1296_CR17","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9780890425596","volume-title":"Diagnostic and Statistical Manual of Mental Disor-ders: DSM-5TM","author":"American Psychiatric Association","year":"2013","unstructured":"American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disor-ders: DSM-5TM. 5th ed. Inc.: American Psychiatric Publishing; 2013.","edition":"5"},{"issue":"3","key":"1296_CR18","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","volume":"12","author":"MF Folstein","year":"1975","unstructured":"Folstein MF, Folstein SE, McHugh PR. \u201cMini-mental state\u201d: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189\u201398. https:\/\/doi.org\/10.1016\/0022-3956(75)90026-6.","journal-title":"J Psychiatr Res"},{"issue":"4","key":"1296_CR19","first-page":"637","volume":"24","author":"L Berg","year":"1988","unstructured":"Berg L. Clinical Dementia Rating (CDR). Psychopharmacol Bull. 1988;24(4):637\u20139.","journal-title":"Psychopharmacol Bull"},{"issue":"1\u20132","key":"1296_CR20","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1300\/J018v05n01_09","volume":"5","author":"JAY Md","year":"1986","unstructured":"Md JAY, Md JIS. 9\/Geriatric Depression Scale (GDS). Clin Gerontol. 1986;5(1\u20132):165\u201373. https:\/\/doi.org\/10.1300\/J018v05n01_09.","journal-title":"Clin Gerontol"},{"issue":"1","key":"1296_CR21","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s40336-015-0102-6","volume":"3","author":"O Sabri","year":"2015","unstructured":"Sabri O, Seibyl J, Rowe C, Barthel H. Beta-amyloid imaging with florbetaben. Clin Transl Imaging. 2015;3(1):13\u201326. https:\/\/doi.org\/10.1007\/s40336-015-0102-6.","journal-title":"Clin Transl Imaging"},{"issue":"8","key":"1296_CR22","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1016\/j.jalz.2015.02.004","volume":"11","author":"O Sabri","year":"2015","unstructured":"Sabri O, Sabbagh MN, Seibyl J, et al. Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer\u2019s disease: Phase 3 study. Alzheimer\u2019s & Dementia. 2015;11(8):964\u201374. https:\/\/doi.org\/10.1016\/j.jalz.2015.02.004.","journal-title":"Alzheimer\u2019s & Dementia"},{"key":"1296_CR23","unstructured":"Bullich S, Catafau A, Senda M, Khodaverdi-Afaghi V, Stephens A. Performance of 18F-Florbetaben PET Image Reading Training in Japanese language. J Nucl Med. 2016;57(supplement 2):1822\u20131822. Accessed 5 Jan 2021. https:\/\/jnm.snmjournals.org\/content\/57\/supplement_2\/1822."},{"issue":"1","key":"1296_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jalz.2014.07.003","volume":"11","author":"WE Klunk","year":"2015","unstructured":"Klunk WE, Koeppe RA, Price JC, et al. The Centiloid Project: standardizing quanti-tative amyloid plaque estimation by PET. Alzheimers Dement. 2015;11(1):1-15.e4. https:\/\/doi.org\/10.1016\/j.jalz.2014.07.003.","journal-title":"Alzheimers Dement"},{"issue":"3","key":"1296_CR25","doi-asserted-by":"publisher","first-page":"e2499","DOI":"10.1002\/brb3.2499","volume":"12","author":"H Matsuda","year":"2022","unstructured":"Matsuda H, Yamao T. Software development for quantitative analysis of brain amy-loid PET. Brain Behav. 2022;12(3):e2499. https:\/\/doi.org\/10.1002\/brb3.2499.","journal-title":"Brain Behav."},{"issue":"1","key":"1296_CR26","doi-asserted-by":"publisher","first-page":"14950","DOI":"10.1038\/s41598-020-70978-z","volume":"10","author":"SH Cho","year":"2020","unstructured":"Cho SH, Choe YS, Park S, et al. Appropriate reference region selection of 18F-florbetaben and 18F-flutemetamol beta-amyloid PET expressed in Centiloid. Sci Rep. 2020;10(1):14950. https:\/\/doi.org\/10.1038\/s41598-020-70978-z.","journal-title":"Sci Rep"},{"issue":"1","key":"1296_CR27","doi-asserted-by":"publisher","first-page":"69","DOI":"10.4103\/1673-5374.125332","volume":"9","author":"L Yi","year":"2014","unstructured":"Yi L, Wu T, Luo W, Zhou W, Wu J. A non-invasive, rapid method to genotype late-onset Alzheimer\u2019s disease-related apolipoprotein E gene polymorphisms. Neural Regen Res. 2014;9(1):69\u201375. https:\/\/doi.org\/10.4103\/1673-5374.125332.","journal-title":"Neural Regen Res"},{"issue":"11","key":"1296_CR28","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1176\/ajp.141.11.1356","volume":"141","author":"WG Rosen","year":"1984","unstructured":"Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer\u2019s disease. Am J Psychiatry. 1984;141(11):1356\u201364. https:\/\/doi.org\/10.1176\/ajp.141.11.1356.","journal-title":"Am J Psychiatry"},{"issue":"3","key":"1296_CR29","first-page":"837","volume":"44","author":"ER DeLong","year":"1988","unstructured":"DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Bi-ometrics. 1988;44(3):837\u201345.","journal-title":"Bi-ometrics"},{"issue":"1","key":"1296_CR30","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s13195-021-00807-6","volume":"13","author":"S Bullich","year":"2021","unstructured":"Bullich S, Ro\u00e9-Vellv\u00e9 N, Marqui\u00e9 M, et al. Early detection of amyloid load using 18F-florbetaben PET. Alzheimers Res Ther. 2021;13(1):67. https:\/\/doi.org\/10.1186\/s13195-021-00807-6.","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"1296_CR31","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s13195-019-0478-z","volume":"11","author":"G Salvad\u00f3","year":"2019","unstructured":"Salvad\u00f3 G, Molinuevo JL, Brugulat-Serrat A, et al. Centiloid cut-off values for optimal agreement between PET and CSF core AD biomarkers. Alzheimers Res Ther. 2019;11(1):27. https:\/\/doi.org\/10.1186\/s13195-019-0478-z.","journal-title":"Alzheimers Res Ther"},{"issue":"17","key":"1296_CR32","doi-asserted-by":"publisher","first-page":"e1647","DOI":"10.1212\/WNL.0000000000008081","volume":"93","author":"SE Schindler","year":"2019","unstructured":"Schindler SE, Bollinger JG, Ovod V, et al. High-precision plasma \u03b2-amyloid 42\/40 predicts current and future brain amyloidosis. Neurology. 2019;93(17):e1647\u201359. https:\/\/doi.org\/10.1212\/WNL.0000000000008081.","journal-title":"Neurology"},{"key":"1296_CR33","doi-asserted-by":"publisher","unstructured":"Rabe C, Bittner T, Jethwa A, et al. Clinical performance and robustness evaluation of plasma amyloid-\u03b242\/40 prescreening. Alzheimers Dement.\u00a0https:\/\/doi.org\/10.1002\/alz.12801. Published online September 2022.","DOI":"10.1002\/alz.12801"},{"issue":"2","key":"1296_CR34","doi-asserted-by":"publisher","first-page":"277","DOI":"10.3233\/JAD-2009-0948","volume":"16","author":"OI Okereke","year":"2009","unstructured":"Okereke OI, Xia W, Irizarry MC, et al. Performance characteristics of plasma amy-loid \u03b2 40 and 42 assays. J Alzheimers Dis. 2009;16(2):277\u201385. https:\/\/doi.org\/10.3233\/JAD-2009-0948.","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"1296_CR35","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1186\/s13195-022-01117-1","volume":"14","author":"AL Brand","year":"2022","unstructured":"Brand AL, Lawler PE, Bollinger JG, et al. The performance of plasma amyloid beta measurements in identifying amyloid plaques in Alzheimer\u2019s disease: a literature review. Alzheimers Res Ther. 2022;14(1):195. https:\/\/doi.org\/10.1186\/s13195-022-01117-1.","journal-title":"Alzheimers Res Ther"},{"key":"1296_CR36","doi-asserted-by":"publisher","unstructured":"Janelidze S, Teunissen CE, Zetterberg H, et al. Head-to-head comparison of 8 plasma amyloid-\u03b2 42\/40 assays in Alzheimer disease. JAMA Neurol. https:\/\/doi.org\/10.1001\/jamaneurol.2021.3180. Published online September 2021.","DOI":"10.1001\/jamaneurol.2021.3180"},{"key":"1296_CR37","doi-asserted-by":"publisher","unstructured":"Teunissen CE, Verberk IMW, Thijssen EH, et al. Blood-based biomarkers for Alz-heimer\u2019s disease: towards clinical implementation. Lancet Neurol. https:\/\/doi.org\/10.1016\/S1474-4422(21)00361-6. Published online November 2021.","DOI":"10.1016\/S1474-4422(21)00361-6"},{"issue":"3","key":"1296_CR38","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/s41591-020-0762-2","volume":"26","author":"EH Thijssen","year":"2020","unstructured":"Thijssen EH, La Joie R, Wolf A, et al. Diagnostic value of plasma phosphorylated tau181 in Alzheimer\u2019s disease and frontotemporal lobar degeneration. Nat Med. 2020;26(3):387\u201397. https:\/\/doi.org\/10.1038\/s41591-020-0762-2.","journal-title":"Nat Med"},{"issue":"5","key":"1296_CR39","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/S1474-4422(20)30071-5","volume":"19","author":"TK Karikari","year":"2020","unstructured":"Karikari TK, Pascoal TA, Ashton NJ, et al. Blood phosphorylated tau 181 as a bi-omarker for Alzheimer\u2019s disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. Lancet Neurol. 2020;19(5):422\u201333. https:\/\/doi.org\/10.1016\/S1474-4422(20)30071-5.","journal-title":"Lancet Neurol"},{"key":"1296_CR40","doi-asserted-by":"publisher","unstructured":"Benedet AL, Mil\u00e0-Alom\u00e0 M, Vrillon A, et al. Differences between plasma and cere-brospinal fluid glial fibrillary acidic protein levels across the Alzheimer disease con-tinuum. JAMA Neurol. https:\/\/doi.org\/10.1001\/jamaneurol.2021.3671. Published online October 2021.","DOI":"10.1001\/jamaneurol.2021.3671"},{"issue":"11","key":"1296_CR41","doi-asserted-by":"publisher","first-page":"3505","DOI":"10.1093\/brain\/awab223","volume":"144","author":"JB Pereira","year":"2021","unstructured":"Pereira JB, Janelidze S, Smith R, et al. Plasma GFAP is an early marker of amyloid-\u03b2 but not tau pathology in Alzheimer\u2019s disease. Brain. 2021;144(11):3505\u201316. https:\/\/doi.org\/10.1093\/brain\/awab223.","journal-title":"Brain"},{"issue":"12","key":"1296_CR42","doi-asserted-by":"publisher","first-page":"2555","DOI":"10.1038\/s41591-022-02074-w","volume":"28","author":"NJ Ashton","year":"2022","unstructured":"Ashton NJ, Janelidze S, Mattsson-Carlgren N, et al. Differential roles of A\u03b242\/40, p-tau231 and p-tau217 for Alzheimer\u2019s trial selection and disease monitoring. Nat Med. 2022;28(12):2555\u201362. https:\/\/doi.org\/10.1038\/s41591-022-02074-w.","journal-title":"Nat Med"},{"issue":"9","key":"1296_CR43","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1038\/s41591-022-01925-w","volume":"28","author":"M Mil\u00e0-Alom\u00e0","year":"2022","unstructured":"Mil\u00e0-Alom\u00e0 M, Ashton NJ, Shekari M, et al. Plasma p-tau231 and p-tau217 as state markers of amyloid-\u03b2 pathology in preclinical Alzheimer\u2019s disease. Nat Med. 2022;28(9):1797\u2013801. https:\/\/doi.org\/10.1038\/s41591-022-01925-w.","journal-title":"Nat Med"}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-023-01296-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13195-023-01296-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-023-01296-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T11:32:39Z","timestamp":1700220759000},"score":1,"resource":{"primary":{"URL":"https:\/\/alzres.biomedcentral.com\/articles\/10.1186\/s13195-023-01296-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,4]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1296"],"URL":"https:\/\/doi.org\/10.1186\/s13195-023-01296-5","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,4]]},"assertion":[{"value":"17 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Certified Review Board of Keio University (#N20170237) approved the study design and protocol. The study was conducted in accordance with the Declaration of Helsinki. All participants (plus their proxies as needed) provided written informed consent for participation in the study. The study was registered with the University Hospital Medical Information Network Clinical Trials Registry (UMIN-CTR;\n                      \n                      , ID# UMIN000032027) and Japan Registry of Clinical Trials (jRCT;\n                      \n                      , ID# jRCTs031180225).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Author YS is employed by Eisai Co., Ltd. The remaining authors report no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"149"}}